- Report
- January 2023
- 170 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Report
- January 2022
- 120 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Report
- January 2019
- 118 Pages
Global
From €3099EUR$3,185USD£2,655GBP
€4427EUR$4,550USD£3,792GBP
- Report
- January 2022
- 115 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- March 2018
- 112 Pages
Global
From €4135EUR$4,250USD£3,542GBP
- Report
- February 2018
- 111 Pages
Global
From €4135EUR$4,250USD£3,542GBP
- Report
- June 2021
Global
From €3892EUR$4,000USD£3,334GBP
- Report
- June 2023
- 102 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- October 2023
- 146 Pages
Global
From €3432EUR$3,528USD£2,940GBP
€4038EUR$4,150USD£3,459GBP
- Report
- March 2024
- 132 Pages
Global
From €924EUR$950USD£792GBP
- Report
- June 2023
- 277 Pages
Global
From €5663EUR$5,820USD£4,851GBP
- Report
- September 2019
Global
From €5225EUR$5,370USD£4,476GBP
- Report
- May 2019
- 293 Pages
Global
From €5225EUR$5,370USD£4,476GBP
The Artificial Pancreas is a medical device that uses biomaterials to regulate blood glucose levels in people with diabetes. It is composed of a continuous glucose monitor (CGM) and an insulin pump, which are connected to a computer algorithm that automatically adjusts insulin delivery. The Artificial Pancreas is designed to mimic the natural pancreas, which produces insulin in response to changes in blood glucose levels. The device is intended to reduce the burden of diabetes management and improve glycemic control.
The Artificial Pancreas market is growing rapidly, driven by increasing prevalence of diabetes, technological advancements, and increasing awareness of the benefits of the device. The market is expected to be further driven by increasing investments in research and development, and the introduction of new products.
Some of the key players in the Artificial Pancreas market include Medtronic, Johnson & Johnson, Insulet Corporation, Dexcom, Tandem Diabetes Care, and Bigfoot Biomedical. Show Less Read more